Elaine V. Morlock, Ph.D.

Patent Agent« back


EDUCATION
  • Ph.D., Molecular and Cellular Pharmacology, University of Wisconsin, Madison, 2012
  • B.S., Molecular and Cellular Biology, Cal Poly, San Luis Obispo, 2007
BAR ADMISSIONS
  • U.S. Patent and Trademark Office (Reg. No. 73,458)
HONORS AND AWARDS
  • 2009-2012, NIH Ruth L. Kirschstein National Research Service Award (NRSA), Individual Predoctoral Fellowship
  • 2007-2008, 2008-2009 Molecular and Cellular Pharmacology NIH Training Grant Fellowship
  • 2007 Lowell E. Hokin Scholarship in Molecular and Cellular Pharmacology
YEAR JOINED FIRM

2017


PRACTICE AREA OVERVIEW

Dr. Morlock prepares and prosecutes U.S. and international patent applications.

TECHNICAL EXPERTISE

Dr. Morlock has prepared and prosecuted patent applications covering biotechnology and pharmaceutical technologies including diagnostic methods, pharmaceutical compositions and excipients, immune therapies, antibody therapeutics, and metabolic engineering.

PRIOR PROFESSIONAL EXPERIENCE

Landon IP (CPA Global), Remote
Patent Analyst | 2016 – 2017

Mintz Levin, San Francisco, CA and Boston
Patent Agent | 2016 – 2016

Alleman, Hall, McCoy, Russell & Tuttle, Portland, OR
Technical Consultant | 2012 – 2013

University of Wisconsin – Madison, Madison, WI
Graduate Research Fellow | 2007 – 2012

Wisconsin Alumni Research Foundation, Madison, WI
Patent Mining Intern | 2009 – 2010

Dartmouth Medical School, Hanover, NH
Laboratory Technician | 2006, 2007

Cal Poly, San Luis Obispo, CA
Student Research | 2006 – 2007

PRESENTATIONS AND PUBLICATIONS
  • Elaine V. Morlock et al. HSD3B and Gene-Gene Interactions in a Pathway-Based Analysis of Genetic Susceptibility to Bladder Cancer. PLoS ONE. Epub December 2012.
  • “Benzodiazepine actions: Teasing apart drug binding from drug efficacy,” American Society for Pharmacology and Experimental Therapeutics Annual Meeting, April 2014
  • Elaine V. Morlock and Cynthia Czajkowski. Different Residues in the GABAA Receptor Benzodiazepine Binding Pocket Mediate Benzodiazepine Efficacy and Binding. Mol Pharmacol. July 2011. Vol. 80. p. 14-22.
  • “Disulfide tethering GABA-A receptor beta subunit loop 9 inhibits channel activation,” Society for Neuroscience Annual Meeting, November 2010
  • “Defining residues involved in the efficacy of benzodiazepine modulation of GABAA receptor current,” Society for Neuroscience Annual Meeting, October 2009
  • Elaine V. Morlock et al. EGFR Pathway Polymorphisms and Bladder Cancer Susceptibility and Prognosis. Carcinogenesis. July 2009. Vol. 30 p. 1155-1160.
  • Elaine V. Morlock et al. SNPs Associated with Bladder Cancer Risk and Prognosis: a Genome-wide Analysis. Hum. Genet. June 2009. Vol 125. p. 527-539.
  • “EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis,” American Association for Cancer Research Conference, April 2009
  • “Defining the pharmacophore for eszopiclone and zolpidem on the GABAA receptor,” Society for Neuroscience Annual Meeting, November 2008
  • Elaine V. Morlock et al. Structural Requirements for Eszopiclone and Zolpidem Binding to the y-aminobutyric acid Type A (GABAA) Receptor are Different. J. Med. Chem. Nov. 2008. Vol. 51. p. 7243–7252.
  • “Genome-wide analysis of SNPs associated with TP53 protein dysregulation in bladder tumors,” American Association of Cancer Research – Frontiers in Cancer Prevention Research Conference, November 2006